Literature DB >> 1348623

P-glycoprotein overexpression cannot explain the complete doxorubicin-resistance phenotype in rat glioblastoma cell lines.

S Huet1, B Schott, J Robert.   

Abstract

We have associated pharmacological studies to a semi-quantitative evaluation of P-glycoprotein(s) expression, to establish if classical multidrug resistance (MDR) could account for the complete resistance phenotype exhibited by progressively doxorubicin-resistant rat glioblastoma cells. Three resistant variants (C6 0.001, C6 0.1 and C6 0.5) of the C6 glioblastoma cell line (C6 S) were selected by long-term culture in the presence of three concentrations of doxorubicin (0.001, 0.1 and 0.5 microgram.ml-1 respectively). The degree of doxorubicin resistance was respectively 7, 33 and 400, and all the cell variants were cross-resistant to m-AMSA, etoposide and vincristine. Doxorubicin incorporation was reduced similarly in all resistant cells, irrespective of the level of resistance. When exposed to their respective doxorubicin IC50, the 7-fold resistant cells had the same intracellular drug incorporation as the sensitive cells, whereas the 33-fold and 400-fold resistant cells could incorporate respectively 3.7 and 17 times more drug. The ratio of doxorubicin exposures required for 50% DNA synthesis inhibition and 50% growth inhibition was dependent on the degree of resistance; this ratio was 12.8 in C6 S, 11.6 in C6 0.001, 6.3 in C6 0.1 and 1.8 in C6 0.5. P-glycoprotein(s) overexpression was of the same magnitude as the resistance factor in variants C6 0.001 and C6 0.1, but was lower than resistance factor in variant C6 0.5. Reversal of drug incorporation by verapamil was complete in all resistant cell lines; however, reversal of doxorubicin cytotoxicity was complete only in the 7-fold resistant line and was only partial in the most resistant lines, which remained 10-fold and 20-fold resistant to doxorubicin. These results suggest that classical MDR was the first phenotype selected by doxorubicin in C6 0.001, whereas mechanism(s) of doxorubicin resistance other than classical MDR are added in the most resistant lines.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1348623      PMCID: PMC1977580          DOI: 10.1038/bjc.1992.111

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  26 in total

1.  Glutathione S-transferases and glutathione peroxidases in doxorubicin-resistant murine leukemic P388 cells.

Authors:  S V Singh; S Nair; H Ahmad; Y C Awasthi; A Krishan
Journal:  Biochem Pharmacol       Date:  1989-10-15       Impact factor: 5.858

2.  Photoaffinity labeling of the multidrug-resistance-related P-glycoprotein with photoactive analogs of verapamil.

Authors:  A R Safa
Journal:  Proc Natl Acad Sci U S A       Date:  1988-10       Impact factor: 11.205

3.  A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants.

Authors:  R L Juliano; V Ling
Journal:  Biochim Biophys Acta       Date:  1976-11-11

4.  Quantitative determination of factors contributing to doxorubicin resistance in multidrug-resistant cells.

Authors:  G J Schuurhuis; H J Broxterman; A Cervantes; T H van Heijningen; J H de Lange; J P Baak; H M Pinedo; J Lankelma
Journal:  J Natl Cancer Inst       Date:  1989-12-20       Impact factor: 13.506

Review 5.  The biochemistry of P-glycoprotein-mediated multidrug resistance.

Authors:  J A Endicott; V Ling
Journal:  Annu Rev Biochem       Date:  1989       Impact factor: 23.643

6.  Expression of the P-glycoprotein gene in multidrug-resistant Chinese hamster ovary cells.

Authors:  T Mukhopadhyay; M T Kuo
Journal:  Anticancer Res       Date:  1989 May-Jun       Impact factor: 2.480

7.  Altered catalytic activity of and DNA cleavage by DNA topoisomerase II from human leukemic cells selected for resistance to VM-26.

Authors:  M K Danks; C A Schmidt; M C Cirtain; D P Suttle; W T Beck
Journal:  Biochemistry       Date:  1988-11-29       Impact factor: 3.162

8.  Differential effect of the calmodulin inhibitor trifluoperazine in modulating cellular accumulation, retention and cytotoxicity of doxorubicin in progressively doxorubicin-resistant L1210 mouse leukemia cells. Lack of correlation between cellular doxorubicin levels and expression of resistance.

Authors:  R Ganapathi; D Grabowski
Journal:  Biochem Pharmacol       Date:  1988-01-15       Impact factor: 5.858

9.  Correlation of multidrug resistance with decreased drug accumulation, altered subcellular drug distribution, and increased P-glycoprotein expression in cultured SW-1573 human lung tumor cells.

Authors:  H G Keizer; G J Schuurhuis; H J Broxterman; J Lankelma; W G Schoonen; J van Rijn; H M Pinedo; H Joenje
Journal:  Cancer Res       Date:  1989-06-01       Impact factor: 12.701

10.  Pharmacological, molecular, and cytogenetic analysis of "atypical" multidrug-resistant human leukemic cells.

Authors:  W T Beck; M C Cirtain; M K Danks; R L Felsted; A R Safa; J S Wolverton; D P Suttle; J M Trent
Journal:  Cancer Res       Date:  1987-10-15       Impact factor: 12.701

View more
  10 in total

1.  Inhibition of protein kinase C in multidrug-resistant cells by modulators of multidrug resistance.

Authors:  Y P Hu; J Robert
Journal:  J Cancer Res Clin Oncol       Date:  1997       Impact factor: 4.553

2.  CD133 and DNA-PK regulate MDR1 via the PI3K- or Akt-NF-κB pathway in multidrug-resistant glioblastoma cells in vitro.

Authors:  G Xi; E Hayes; R Lewis; S Ichi; B Mania-Farnell; K Shim; T Takao; E Allender; C S Mayanil; T Tomita
Journal:  Oncogene       Date:  2015-03-30       Impact factor: 9.867

Review 3.  Cellular models for multiple drug resistance in cancer.

Authors:  M Clynes
Journal:  In Vitro Cell Dev Biol       Date:  1993-03

Review 4.  Sphingolipid abnormalities in cancer multidrug resistance: Chicken or egg?

Authors:  Wing-Kee Lee; Richard N Kolesnick
Journal:  Cell Signal       Date:  2017-07-04       Impact factor: 4.315

Review 5.  Human cell lines as models for multidrug resistance in solid tumours.

Authors:  M Clynes; M Heenan; K Hall
Journal:  Cytotechnology       Date:  1993       Impact factor: 2.058

6.  Direct evaluation of intracellular accumulation of free and polymer-bound anthracyclines.

Authors:  T Bogush; G Smirnova; I Shubina; A Syrkin; J Robert
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

7.  Effects of the combination of camptothecin and doxorubicin or etoposide on rat glioma cells and camptothecin-resistant variants.

Authors:  V Pavillard; D Kherfellah; S Richard; J Robert; D Montaudon
Journal:  Br J Cancer       Date:  2001-09-28       Impact factor: 7.640

8.  Single-cell Western blotting after whole-cell imaging to assess cancer chemotherapeutic response.

Authors:  Chi-Chih Kang; Jung-Ming G Lin; Zhuchen Xu; Sanjay Kumar; Amy E Herr
Journal:  Anal Chem       Date:  2014-10-01       Impact factor: 6.986

9.  Flow cytometric analysis of early steps in development of adriamycin resistance in a human gastric cancer cell line.

Authors:  S Tanaka; K Aizawa; N Katayanagi; O Tanaka
Journal:  Jpn J Cancer Res       Date:  1994-01

10.  In Vitro Evaluation of the Cytotoxic Effect of Streptococcus pyogenes Strains, Protegrin PG-1, Cathelicidin LL-37, Nerve Growth Factor and Chemotherapy on the C6 Glioma Cell Line.

Authors:  Alexandr N Chernov; Anna Tsapieva; Diana A Alaverdian; Tatiana A Filatenkova; Elvira S Galimova; Mariia Suvorova; Olga V Shamova; Alexander N Suvorov
Journal:  Molecules       Date:  2022-01-17       Impact factor: 4.411

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.